Metabolic receptor research
AOD-9604 Dosage, Protocol & Research Guide
- MW 1,815.1 g/mol
- CAS 221231-10-3
Dose overview
Every range below is taken from the cited source and carries its evidence grade.
Human data and community reports
| Source | Population | Dose | Frequency | Route | Duration | Evidence |
|---|---|---|---|---|---|---|
| Stier et al., J Endocrinol Metab 2013 (doi 10.4021/jem157w), six placebo-controlled trials[2] | human502 obese adults (BMI 30-45) randomized in a 24-week trial | 0.25–1 mg[2]oral, parallel arms of 0.25, 0.5 and 1 mg daily | daily for 24 weeks | oral | — | Human clinical trialStudy details from the source: Stier et al., J Endocrinol Metab 2013 (doi 10.4021/jem157w), six placebo-controlled trials: METAOD006, 502 obese adults randomized to oral tablets of 0.25, 0.5 or 1 mg daily or placebo for 24 weeks after a 4-week placebo run-in |
| Same paper, METAOD005[2] | human300 obese males and females of non-child-bearing potential | 1–30 mg[2]oral, parallel arms of 1, 5, 10, 20 and 30 mg daily | once daily for 12 weeks | oral | — | Human clinical trialStudy details from the source: Same paper, METAOD005: 300 obese adults (BMI 35 or more) took oral capsules of AOD9604 1, 5, 10, 20 or 30 mg or placebo once daily for 12 weeks after a 2-week placebo run-in (n=50 per group) |
| Human review or observational report[3] | humansubjects in a 12-week randomized clinical trial (population not described by the review) | 1 mg[3]oral, dose as described secondhand by a review | daily | oral | — | Human review or observational reportStudy details from the source: Review (Curr Cardiol Rev 2013, doi 10.2174/157340313805076322) describing a 12-week randomized clinical trial in which subjects received AOD-9604 1 mg/d; the review calls the compound orally active and does not report the trial's subject number |
| Frontiers in Endocrinology 2026 review (doi 10.3389/fendo.2026.1822475) table[4] | humanintravenous entry: population not stated in the review table; oral entry: obese patients | 25–400 mcg[4]intravenous infusion (25-400 mcg); oral (1 mg); intravenous entry is a single administration of 25-400 mcg; the same table lists 1 mg orally once daily for 12 weeks in obese patients | single administration (intravenous); once daily (oral) | other | — | Human review or observational reportStudy details from the source: Frontiers in Endocrinology 2026 review (doi 10.3389/fendo.2026.1822475) table: 25-400 µg intravenous infusion as a single administration; 1 mg orally once daily for 12 weeks in obese patients |
Evidence grades: A approved label, B human trial, C observational, D animal study, E community-reported.
Reconstitution calculator
Calculator example, not a recommended amount
- Concentration
- 2.5 mg/mL
- Volume to draw
- 0.1 mL
- Units on a U-100 syringe
- 10 units
Properties
- CAS
- 221231-10-3
- Molecular weight
- 1,815.1 g/mol
- Formula
- Not yet recorded
- Sequence
- YLRIVQCRSVEGSCGF (disulfide Cys7-Cys14)
- Aliases
- AOD9604
- Vial sizes (mg)
- 5, 10
Storage
Lyophilised (dry powder)
-20 °C; supplied as a solid (Cayman Chemical AOD-9604 (acetate), item 36790).[5]
Storage notes
- Lyophilized
- Not yet recorded from a cited source
- Reconstituted stability (days)
- Not yet recorded from a cited source
Side effects, contraindications and regulatory status
Reported side effects
- Summary of six placebo-controlled trials (about 900 adults; intravenous and oral routes only; sponsor-affiliated authors): the authors report no drug-related withdrawals or serious adverse events and no anti-AOD9604 antibodies in the subset tested.[2] Human trial
- In a 7-day oral multiple-dose study (9, 27 or 54 mg daily; 36 obese males) the 54 mg group had more headaches, diarrhea and flatulence than the 9 mg, 27 mg and placebo groups; the authors link the highest dose to more GI-related events.[2] Human trial
- 24-week oral tablet trial (0.25, 0.5 or 1 mg daily; 502 randomized): 78.7% had at least one adverse event (83.2% placebo, 75.6% at 0.25 mg); 18 patients (3.6%) had a serious event, spread across groups (placebo 8, 0.25 mg 3, 0.5 mg 1, 1 mg 6).[2] Human trial
- 12-week oral trial (1 to 30 mg daily; 300 obese adults): 5 serious events, all neoplasms (20 mg group: basal cell carcinoma, lipoma, squamous cell carcinoma; 10 mg: malignant melanoma; 5 mg: breast cancer); the investigator judged none related to study medication.[2] Human trial
- FDA safety-risk page (current 2026-04-22), nominated-but-withdrawn table: FDA has identified no, or only limited, safety-related information, and also serious adverse events that may be associated with AOD-9604, causality not clear.[1] Regulator or expert-panel statement
Regulatory status
Listed in the nominated-but-withdrawn table of the FDA bulk-substance safety-risk page (content current 2026-04-22). Checked 2026-10-20.[1] Source
Report any adverse reaction to a qualified healthcare professional.
What the research says
Summaries of the cited studies, each with its evidence grade.
Stier et al., J Endocrinol Metab 2013 (doi 10.4021/jem157w), six placebo-controlled trials[2]
Stier et al., J Endocrinol Metab 2013 (doi 10.4021/jem157w), six placebo-controlled trials: METAOD006, 502 obese adults randomized to oral tablets of 0.25, 0.5 or 1 mg daily or placebo for 24 weeks after a 4-week placebo run-in
pmc.ncbi.nlm.nih.gov[3]
Review (Curr Cardiol Rev 2013, doi 10.2174/157340313805076322) describing a 12-week randomized clinical trial in which subjects received AOD-9604 1 mg/d; the review calls the compound orally active and does not report the trial's subject number
Frontiers in Endocrinology 2026 review (doi 10.3389/fendo.2026.1822475) table[4]
Frontiers in Endocrinology 2026 review (doi 10.3389/fendo.2026.1822475) table: 25-400 µg intravenous infusion as a single administration; 1 mg orally once daily for 12 weeks in obese patients
Compare vial sizes
| Size | Price | Doses available from the vial Calculated | Cost per dose Calculated |
|---|---|---|---|
| 10 mg | $24.99 | — | — |
Cost per dose uses the listed partner price and the reference dose cited on this page. Prices change; check the product page.
Calculated from a default of 2 mL water (adjustable).
PeptideCheck may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.
Frequently asked questions
What dose figures are published for AOD-9604?
Cited figures on this page: 0.25-1 mg daily for 24 weeks, oral, parallel arms of 0.25, 0.5 and 1 mg daily [2] (Human clinical trial, evidence grade B); 1-30 mg once daily for 12 weeks, oral, parallel arms of 1, 5, 10, 20 and 30 mg daily [2] (Human clinical trial, evidence grade B); 1 mg daily, oral, dose as described secondhand by a review [3] (Human review or observational report, evidence grade C). These are summaries of published sources, not medical advice. Each figure links to its source in the references.
How is lyophilised AOD-9604 stored?
Cited storage for the lyophilised vial: -20 °C; supplied as a solid (Cayman Chemical AOD-9604 (acetate), item 36790)..
What study duration is cited for AOD-9604?
The cited duration is 12 weeks, with no off period stated (Human review or observational report). It describes the source, not a recommendation.
What is the regulatory status of AOD-9604?
Listed in the nominated-but-withdrawn table of the FDA bulk-substance safety-risk page (content current 2026-04-22). Checked 2026-10-20.
Compound facts
What is the molecular weight of AOD-9604?
What is the CAS number of AOD-9604?
How is AOD-9604 stored in the laboratory?
References
Numbered sources used on this page. Markers in the text link here.
- fda.gov Regulator or expert-panel statement
- Stier et al., J Endocrinol Metab 2013 (doi 10.4021/jem157w), six placebo-controlled trials jofem.org Human trial
- pmc.ncbi.nlm.nih.gov Observational
- Frontiers in Endocrinology 2026 review (doi 10.3389/fendo.2026.1822475) table pmc.ncbi.nlm.nih.gov Observational
- caymanchem.com Manufacturer documentation
Vial sizes and protocols
10 mgPartner size
Available from Pepcore
Supplied as research material for laboratory use only.
- Shop at PepcoreCoupon code
LAUNCH20
PeptideCheck may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.